Next Article in Journal
Mantonico and Pecorello Grape Seed Extracts: Chemical Characterization and Evaluation of In Vitro Wound-Healing and Anti-Inflammatory Activities
Next Article in Special Issue
COVID-19: An Update about the Discovery Clinical Trial
Previous Article in Journal
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
Previous Article in Special Issue
COVID-19: A Brief Overview of the Discovery Clinical Trial

The Rationale for Potential Pharmacotherapy of COVID-19

Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAE
College of Medicine, Cairo University, Cairo 12613, Egypt
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(5), 96;
Received: 22 April 2020 / Revised: 9 May 2020 / Accepted: 11 May 2020 / Published: 14 May 2020
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread rapidly all over the world. COVID-19 is being increasingly investigated through virology, epidemiology, and clinical management strategies. There is currently no established consensus on the standard of care in the pharmacological treatment of COVID-19 patients. However, certain medications suggested for other diseases have been shown to be potentially effective for treating this infection, though there has yet to be clear evidence. Therapies include new agents that are currently tested in several clinical trials, in addition to other medications that have been repurposed as antiviral and immune-modulating therapies. Previous high-morbidity human coronavirus epidemics such as the 2003 SARS-CoV and the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically be active against the emerging coronavirus SARS-CoV-2. Moreover, advances in molecular biology techniques and computational analysis have allowed for the better recognition of the virus structure and the quicker screening of chemical libraries to suggest potential therapies. This review aims to summarize rationalized pharmacotherapy considerations in COVID-19 patients in order to serve as a tool for health care professionals at the forefront of clinical care during this pandemic. All the reviewed therapies require either additional drug development or randomized large-scale clinical trials to be justified for clinical use. View Full-Text
Keywords: COVID-19; SARS-CoV-2; remdesivir; chloroquine; lopinavir; favipiravir; baricitinib; interferons; ACE2; TMPRSS2 COVID-19; SARS-CoV-2; remdesivir; chloroquine; lopinavir; favipiravir; baricitinib; interferons; ACE2; TMPRSS2
Show Figures

Graphical abstract

MDPI and ACS Style

Saber-Ayad, M.; Saleh, M.A.; Abu-Gharbieh, E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals 2020, 13, 96.

AMA Style

Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals. 2020; 13(5):96.

Chicago/Turabian Style

Saber-Ayad, Maha, Mohamed A. Saleh, and Eman Abu-Gharbieh. 2020. "The Rationale for Potential Pharmacotherapy of COVID-19" Pharmaceuticals 13, no. 5: 96.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop